Evidence map›Paper›PMID 27936047›Full record

ArticlePloS one2016

Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene.

Dalziza Victalina de Almeida, Karine Venegas Macieira, Beatriz Gilda Jegerhorn Grinsztejn, Valdiléa Gonçalves Veloso Dos Santos, Monick Lindenmeyer Guimarães

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dalziza Victalina de AlmeidaLaboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute - FIOCRUZ, Rio de Janeiro, Brazil.
Karine Venegas MacieiraLaboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute - FIOCRUZ, Rio de Janeiro, Brazil.
Beatriz Gilda Jegerhorn GrinsztejnNational Institute of Infectology/ FIOCRUZ, Rio de Janeiro, Brazil.
Valdiléa Gonçalves Veloso Dos SantosNational Institute of Infectology/ FIOCRUZ, Rio de Janeiro, Brazil.
Monick Lindenmeyer GuimarãesLaboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute - FIOCRUZ, Rio de Janeiro, Brazil.
Fundação Oswaldo Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various HIV-1 env genetic and biochemical features impact the elicitation of cross-reactive neutralizing antibodies in natural infections. Thus, we aimed to investigate cross-neutralizing antibodies in individuals infected with HIV-1 env subtypes B, F1, C or the B/Bbr variant as well as env characteristics. Therefore, plasma samples from Brazilian chronically HIV-1 infected individuals were submitted to the TZM-bl neutralization assay. We also analyzed putative N-glycosylation sites (PNGLs) and the size of gp120 variable domains in the context of HIV-1 subtypes prevalent in Brazil. We observed a greater breadth and potency of the anti-Env neutralizing response in individuals infected with the F1 or B HIV-1 subtypes compared with the C subtype and the variant B/Bbr. We observed greater V1 B/Bbr and smaller V4 F1 than those of other subtypes (p<0.005), however neither was there a correlation verified between the variable region length and neutralization potency, nor between PNLG and HIV-1 subtypes. The enrichment of W at top of V3 loop in weak neutralizing response viruses and the P in viruses with higher neutralization susceptibility was statistically significant (p = 0.013). Some other signatures sites were associated to HIV-1 subtype-specific F1 and B/Bbr samples might influence in the distinct neutralizing response. These results indicate that a single amino acid substitution may lead to a distinct conformational exposure or load in the association domain of the trimer of gp120 and interfere with the induction power of the neutralizing response, which affects the sensitivity of the neutralizing antibody and has significant implications for vaccine design.

Indexed as

Antibodies, NeutralizingBrazilenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHumansPhylogenyAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Identifiers

PMID27936047
PMCPMC5147934
OpenAlexW2560267295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.